Filing Flows › Vivos Therapeutics (VVOS) › Product revenue
Vivos Therapeutics (VVOS) Product revenue by quarter
Vivos Therapeutics' Product revenue was $1.4M in Q2 2026 (second quarter 2026), -6% from Q1 2026. Over the last 6 quarters it ranged from $1.4M (Q2 2026) to $2.3M (Q4 2024).
| Quarter | Product revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $1.4M | -6% | -28% |
| Q1 2026 | $1.4M | -34% | -21% |
| Q3 2025 | $2.2M | +16% | — |
| Q2 2025 | $1.9M | +4% | — |
| Q1 2025 | $1.8M | -20% | — |
| Q4 2024 | $2.3M | — | — |
Q2 2026 at a glance
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vivos Therapeutics' Product revenue?
Vivos Therapeutics' Product revenue was $1.4M in Q2 2026 (second quarter 2026), -6% from Q1 2026.
How has Vivos Therapeutics' Product revenue changed?
Over the last 6 quarters it ranged from $1.4M (Q2 2026) to $2.3M (Q4 2024).